| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_285d84c590a5862a0fd7d2bf29381f6e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2019-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_126be2b3c23a09f3ebb81784cfee384d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d936f456c6522cad8efa29e1ba56403e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab15f83d4c32e49f8503993928c85400 |
| publicationDate |
2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200119834-A |
| titleOfInvention |
Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies |
| abstract |
A regimen for treating CD20+ cancer, particularly lymphoma, is disclosed. This regimen involves several cycles of administration of anti-CD20 and anti-CD47 antibodies at appropriate doses and dosing intervals. |
| priorityDate |
2018-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |